Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
Company Details
- Employees
- 5
- Address
- Zürich, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.baxiva.com
- HQ
- Zürich
Baxiva Questions
Baxiva's website is http://www.baxiva.com
Baxiva's LinkedIn profile is https://ch.linkedin.com/company/baxiva
Baxiva has
5 employees.
View email and phone details for 5
employees at Baxiva.
Baxiva's industry is
Biotechnology Research
Baxiva's top competitors are
Xlife Sciences Ag,
Sciencepreneurship,
Araris Biotech Ag,
Cellx Biosolutions,
Apy Therapeutics, Llc,
Nouscom,
Alpioner Therapeutics,
Alfasigma,
Adina Technologies,
Novartis.
Baxiva's categories are Biotechnology Research
